Frontier Analysis of Innovative Drug Empagliflozin

Wei-Xing Chen （ Patent Examination Cooperation (Beijing) Center of the Patent Office, CNIPA, Beijing, 100070, China ）

Abstract

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor used in the treatment of type 2 diabetes mellitus (T2DM). Its advantages lie not only in lowering blood glucose but also in reducing the risk of cardiovascular death. A hallmark of innovative drugs is their associated patent protection. This paper presents a statistical and analytical overview of invention patents related to empagliflozin in China, covering aspects such as key applicants, applicant nationalities, application trends over the past 20 years, technological field distribution, and patent tagging. The goal is to understand trends, hotspots, and focal points in the technological development of innovative drugs related to empagliflozin. Special attention is given to the patent applications of Boehringer Ingelheim International GmbH, a representative applicant in this field. Since patents represent the frontline layout of innovative drugs, this frontier analysis of empagliflozin provides a valuable reference for pharmaceutical research and development.

Keywords

Full Text

References